Cargando…

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

BACKGROUND: Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aoki, Masahiko, Shoji, Hirokazu, Nagashima, Kengo, Imazeki, Hiroshi, Miyamoto, Takahiro, Hirano, Hidekazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Higuchi, Kazuhide, Boku, Narikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555603/ https://www.ncbi.nlm.nih.gov/pubmed/31231567 http://dx.doi.org/10.1136/esmoopen-2019-000488

Ejemplares similares

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
por: Masuda, Ken, et al.
Publicado: (2019)

Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab
por: Kadono, Toru, et al.
Publicado: (2023)

Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
por: Oshima, Kotoe, et al.
Publicado: (2022)

Tumor growth rate during re-challenge chemotherapy with previously used agents as salvage treatment for metastatic colorectal cancer: A retrospective study
por: Ishikawa, Masashi, et al.
Publicado: (2021)

Case report: potential treatment of metastatic amphicrine carcinoma of the rectum with FOLFOXIRI chemotherapy
por: Tamura, Nobumasa, et al.
Publicado: (2020)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy
por: Honma, Yoshitaka, et al.
Publicado: (2019)

Immune status at pre-treatment impacts on progression-free survival of metastatic colorectal cancer patients treated with first-line chemotherapy
por: Tada, Kohei, et al.
Publicado: (2015)

Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
por: Watanabe, Sho, et al.
Publicado: (2019)

Esophageal Metastasis from Rectal Cancer Successfully Treated with Fluorouracil-Based Chemotherapy with Bevacizumab: A Case Report and Review of the Literature
por: Watanabe, Sho, et al.
Publicado: (2017)

Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection
por: Shoji, Hirokazu, et al.
Publicado: (2014)

Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)
por: Iwasa, Satoru, et al.
Publicado: (2020)

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy
por: Shoji, Hirokazu, et al.
Publicado: (2017)

Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer
por: Kudo-Saito, Chie, et al.
Publicado: (2022)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2015)

A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
por: Shoji, Hirokazu, et al.
Publicado: (2021)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
por: Kang, Yoon-Koo, et al.
Publicado: (2022)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Relationship between cervical esophageal squamous cell carcinoma and human papilloma virus infection and gene mutations
por: Fukahori, Masaru, et al.
Publicado: (2021)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

CD11b(+)CTLA4(+) myeloid cells are a key driver of tumor evasion in colorectal cancer
por: Imazeki, Hiroshi, et al.
Publicado: (2021)

Comprehensive characterization of the phosphoproteome of gastric cancer from endoscopic biopsy specimens
por: Abe, Yuichi, et al.
Publicado: (2020)

Temporal dynamics from phosphoproteomics using endoscopic biopsy specimens provides new therapeutic targets in stage IV gastric cancer
por: Hirano, Hidekazu, et al.
Publicado: (2022)

Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series
por: Kanazu, Masaki, et al.
Publicado: (2018)

Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer
por: Imaizumi, Jun, et al.
Publicado: (2023)

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
por: Osumi, Hiroki, et al.
Publicado: (2022)

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial
por: Morizane, Chigusa, et al.
Publicado: (2022)

Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report
por: Ogata, Takatsugu, et al.
Publicado: (2018)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Prognostic factors of brain metastases from colorectal cancer
por: Imaizumi, Jun, et al.
Publicado: (2019)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan
por: Aoki, Masahiko, et al.
Publicado: (2022)

Case report: Irinotecan-induced interstitial lung disease in an advanced colorectal cancer patient resurfacing decades after allogeneic bone marrow transplantation for aplastic anemia; a case report and narrative review of literature
por: Baba, Keisuke, et al.
Publicado: (2023)

Comparison of model fit and discriminatory ability of M category as defined by the 7th and 8th editions of the tumor‐node‐metastasis classification of colorectal cancer and the 9th edition of the Japanese classification
por: Shida, Dai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ivkic3lfkfi8028v5q9osrbn2s